Brokerage Firm Rating Update on AbbVie (ABBV)

AbbVie (ABBV) : 14 analysts are covering AbbVie (ABBV) and their average rating on the stock is 2.21, which is read as a Buy. 6 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. AbbVie (ABBV) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

AbbVie (ABBV) : Average target price received by AbbVie (ABBV) is $72.54 with an expected standard deviation of $11.04. The most aggressive target on the stock is $90, whereas the most downbeat target is $47. 13 financial analysts are currently covering the stock.


For the current week, the company shares have a recommendation consensus of Buy. Also, Raymond James initiates coverage on AbbVie (NYSE:ABBV). Raymond James has a Outperform rating on the shares. As per the latest report, the brokerage house announces the price target to $82 per share. The rating by the firm was issued on September 2, 2016.

AbbVie (NYSE:ABBV): The stock opened at $64.37 and touched an intraday high of $65.14 on Wednesday. During the day, the stock corrected to an intraday low of $64.29, however, the bulls stepped in and pushed the price higher to close in the green at $64.97 with a gain of 0.56% for the day. The total traded volume for the day was 5,714,320. The stock had closed at $64.61 in the previous trading session.

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.